Nitric oxide synthase inhibition in the histamine headache model.
Histamine has been widely used experimentally to induce headache in healthy subjects and migraine in migraineurs. There is evidence that the vascular effects of histamine are at least partially mediated by nitric oxide (NO). Hence we hypothesized that subjective symptoms and hemodynamic effects of histamine could be reduced by systemic NO-synthase inhibition. We therefore studied the effect of pretreatment with N-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of NO-synthase, or placebo on headache, flush and discomfort scores during histamine infusion. Additionally, blood flow velocities in the middle cerebral and the ophthalmic artery and ocular fundus pulsations were measured. Whereas L-NMMA blunted the effect of histamine in the ophthalmic artery and the ocular circulation, NO-synthase inhibition did not mitigate subjective symptoms. Histamine did not affect mean blood flow velocities in the middle cerebral artery. Hence, we conclude that NO-synthase inhibition reduces the histamine-induced vascular effects in the ocular circulation, but is not sufficient to attenuate or abort the subjective symptoms provoked by histamine infusion.
Schmetterer
L
L
Department of Clinical Pharmacology, Währinger Gürtel, Vienna, Austria.
Wolzt
M
M
Graselli
U
U
Findl
O
O
Strenn
K
K
Simak
S
S
Kastner
J
J
Eichler
H G
HG
Singer
E A
EA
D000328:Adult; D004311:Double-Blind Method; D006261:Headache / Q000188:drug therapy*; D006632:Histamine / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008959:Models, Neurological; D019001:Nitric Oxide Synthase / Q000187:drug effects*; D019323:omega-N-Methylarginine / Q000494:pharmacology*
D019323:omega-N-Methylarginine; D006632:Histamine; D019001:Nitric Oxide Synthase